IFNB1 presents an intriguing target for SLE therapy because of the predominance of its signature in SLE affected tissues, its unique signaling properties and cellular expression, and its potential role in B cell development and tolerance68,69. The gene discussed is IFNB1; the disease is systemic lupus erythematosus.